Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...' Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .
2 Cash-Producing Stocks Worth Investigating and 1 to Brush Off A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
2 Growth Stocks to Buy Hand Over Fist in July These companies are poised to produce fireworks for your portfolio over the coming years.
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
